Highlights
1 patent
About
Therapeutic Target for Treating Neurogenetic Disorders
GSKure is an IP-based company that owns innovative proprietary GSK-3 peptide inhibitor drug candidates.
The company's Kure products are based on a novel design of compounds that target a unique region at the GSK-3 protein surface termed the substrate binding site. The substrate-competitive inhibitors (SCIs) show improved selectivity and low toxicity compared to traditional ATP-competitive inhibitors.
GSKures novel SCI strategy for drug design offers significant advantages for clinical practice. Professor Hagit Eldar-Finkelman of Tel Aviv University conducted pioneering studies in developing GSK-3 inhibitors and their therapeutic use in treating human disease.
Identity
| Name | GSKure |
|---|---|
| Slug | cerebramed |
| Former names | Cerebramed |
| Type / kind | startup |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwI6s-oIKDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Tel Aviv-Yafo, Israel |
Web & social
| Website | http://gskure.com/ |
|---|
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsMolecules
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticalsBiotechnologyHealthcarePatients
Business models
B2B
Tags
drug-discoveryneurosciencealzheimers-diseaseamyotrophic-lateral-sclerosis-alsdegenerative-diseasesdrug-designpatientspharma-companies
Funding
| Total raised | — |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}